Breakthrough Clinical Trial Shows Therapeutic Plasma Exchange Can Rejuvenate Biological Age

A pioneering clinical study has demonstrated that therapeutic plasma exchange (TPE), especially when combined with intravenous immunoglobulin (IVIG), can lead to a significant reduction in biological age. The trial, conducted under a single-blind, placebo-controlled design, revealed an average decrease of 2.6 years in biological age as measured by advanced multi-omics biomarkers. Published in the journal Aging Cell, this research highlights the potential of TPE as a promising intervention for aging and age-related diseases.

Led by scientists from Circulate Health and the Buck Institute for Research on Aging, the study explored how TPE influences vital molecular and cellular markers associated with aging. TPE involves removing, filtering, and replacing a patient's plasma, a process that has traditionally been used to treat certain blood conditions. Now, evidence suggests that it might also reverse aspects of biological aging.

Participants were assigned to four different groups: biweekly TPE, biweekly TPE combined with IVIG, monthly TPE, and a control group. Results showed that those receiving TPE with IVIG experienced the most significant reduction, averaging 2.61 years in biological age compared to 1.32 years for TPE alone. Additionally, improvements were noted in immune cell profiles, markers of cellular senescence, and physical health metrics such as balance and strength.

Importantly, individuals with poorer baseline health markers, like elevated bilirubin and glucose levels, exhibited the greatest rejuvenation effects. Although the most pronounced benefits occurred early in the treatment course, the study observed diminishing returns with subsequent sessions, suggesting options for optimizing treatment schedules.

Researchers emphasize that this study marks the first comprehensive multi-omics investigation into how plasma exchange can influence aging at a molecular level. The findings support the potential for personalized therapeutic strategies targeting biological age, opening new avenues for extending healthspan and managing age-related decline.

"This research provides compelling evidence that plasma exchange combined with IVIG can serve as a powerful tool for reversing biological aging," said Dr. Brad Younggren, CEO of Circulate. The study underscores the importance of developing targeted interventions that address the underlying molecular mechanisms of aging, with the goal of improving overall health and longevity.

For more details, the full study can be accessed through Aging Cell here. This groundbreaking work demonstrates the potential of plasma-based therapies in the future landscape of anti-aging medicine, with promising implications for various age-related conditions.